brivaracetam / Generic mfg. - LARVOL DELTA

Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics. (PubMed, Brain) - "For focal epilepsies, first-line ASMs achieved similar rates of seizure freedom, but levetiracetam remained superior to lamotrigine and oxcarbazepine for retention (p < 0.001); among second-line ASMs, topiramate and lacosamide were both superior to zonisamide for seizure freedom (p < 0.001), while lacosamide remained superior to topiramate and zonisamide for retention (p < 0.002); among third-line ASMs, cenobamate, brivaracetam, and clobazam achieved similar retention and seizure freedom. In conclusion, emulated clinical trials provide a useful framework for studying the comparative effectiveness of antiseizure medications using real-world observational data. Our findings of differences in seizure freedom and retention between ASMs help generate hypotheses that should be tested in future prospective, randomized comparative effectiveness trials."

HEOR • Journal • CNS Disorders • Epilepsy

Real-world retention of newer ASMs, including lacosamide and brivaracetam as first or second therapies in adult-onset epilepsy. (PubMed, Epilepsia) - "Lacosamide and brivaracetam have at least similar real-world retention as lamotrigine or levetiracetam when used early in adult-onset epilepsy. This widens the therapeutic arsenal and the possibility of tailored ASM selection."

Journal • Real-world evidence • CNS Disorders • Epilepsy

Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United States. (PubMed, Epilepsy Behav) - "Brivaracetam was effective in patients with difficult-to-control focal-onset seizures; as shown by brivaracetam retention at 12 months. Improvements in PROs were seen early. Brivaracetam was well-tolerated and no new safety signals were observed."

Journal • Observational data • CNS Disorders • Epilepsy

Initiating Estradiol Hormone Therapy in a Transgender Woman With Multifocal Idiopathic Localization-Related Epilepsy (ENDO 2025) - "At the time of presentation, she was on lamotrigine 150 mg and brivaracetam 50 mg twice daily for epilepsy.After discussing the risks and benefits of E2 with the patient and her neurologist, the patient was started on low-dose transdermal E2 0.05 mg/day twice-weekly patch to relieve ongoing gender dysphoria while closely monitoring for seizures...She noted some seizures since starting progesterone, though not worse than prior...Through careful monitoring and management of GAHT and close communication with neurology, the patient has achieved personally satisfactory outcomes with GAHT with her epilepsy overall stable. Our case highlights the importance of multidisciplinary care and safety in starting E2 GAHT in transgender patients with epilepsy."

Clinical • CNS Disorders • Epilepsy

Drug-resistant Epilepsy: Which Drugs are Substrates of P-glycoprotein and Which are Not? (PubMed, Curr Neuropharmacol) - "among the anticrisis medications, the following are likely substrates of P-glycoprotein: Phenytoin, Phenobarbital, Oxcarbazepine, Lamotrigine, Topiramate, and Lacosamide (less evidence). The following are probably not substrates: Brivaracetam, Zonisamide, Valproic acid, Perampanel, Gabapentin, and Vigabatrin. We have not obtained enough information about: Carbamazepine, Eslicarbazepine, Levetiracetam, Tiagabine, Felbamate, Pregabalin, Rufinamide, Ezogabine, and Retigabine."

Journal • CNS Disorders • Epilepsy

Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration. (PubMed, Front Neurol) - "The most common ASMs were voltage-gated sodium channel blockers (VGSC), Levetiracetam (LEV)/Brivaracetam (BRV) synaptic vesicle protein 2A (SV2A) inhibitors, and Perampanel (PER). It can be prescribed to patients on conventional therapy who are still having seizures and have failed two or more other ASMs. By reporting experiences of CNB titration, seizure, and drug load reduction outcomes in office-based neurology, this study will give German office-based outpatient neurologists evidence to support both CNB and other third-generation ASM use in their practice."

Journal • Real-world evidence • CNS Disorders • Epilepsy

Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population. (PubMed, Epilepsy Behav) - "In a population of veterans with epilepsy, clinicians should exercise caution in monitoring for cognitive and psychiatric adverse effects prescribed with the newer ASMs. Further research could help elucidate the dosage and delay at which these side effects would occur after treatment initiation."

Adverse events • Journal • CNS Disorders • Cognitive Disorders • Developmental Disorders • Epilepsy • Psychiatry

Brivaracetam, Another Useful Antiseizure Medication. (PubMed, J Epilepsy Res) - No abstract available

Journal • CNS Disorders • Epilepsy

Brivaracetam: Pharmacology, Clinical Efficacy, and Safety in Epilepsy. (PubMed, J Epilepsy Res) - "Brivaracetam, a high-affinity synaptic vesicle 2A (SV2A) ligand and propyl analog of levetiracetam, has been approved as an adjunctive and monotherapy option for focal onset seizures in various age groups. Future research should further investigate brivaracetam's utility in broader patient groups to better understand its long-term safety and expand its therapeutic reach. With its unique pharmacological properties, clinical flexibility, and promising safety profile, brivaracetam stands as a valuable addition to current epilepsy treatment options, addressing several unmet needs in seizure management."

Journal • Review • Cardiovascular • CNS Disorders • Epilepsy

Safety, Tolerability, and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients with Focal-Onset Seizures: Interim Analysis of a Phase 3 Open-Label Extension Trial. (PubMed, Adv Ther) - P3 | "Based on this interim and post hoc analysis, long-term adjunctive BRV was well tolerated and efficacious in Japanese and Chinese patients with FOS. The efficacy response was maintained over time in those completing 12 and 24 months of trial participation. Overall, 68% of patients remained on BRV treatment for 3 years."

Journal • P3 data • P3 data: top line • CNS Disorders • Epilepsy

Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial. (PubMed, Pain Rep) - "These findings suggest safety, tolerability, and feasibility of brivaracetam for treating neuropathic pain in spinal cord injury. These pilot findings will be used to power future efficacy clinical trials."

Clinical • Journal • CNS Disorders • Fatigue • Neuralgia • Orthopedics • Pain

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (clinicaltrials.gov) - P3 | N=70 | Recruiting | Sponsor: UCB Biopharma SRL | Trial completion date: Jul 2029 ➔ Jul 2030 | Trial primary completion date: Jul 2029 ➔ Jul 2030

Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy • Pediatrics

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures (clinicaltrials.gov) - P3 | N=70 | Recruiting | Sponsor: UCB Biopharma SRL | Active, not recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Epilepsy • Pediatrics

Distribution of NECAB1-Positive Neurons in Normal and Epileptic Brain-Expression Changes in Temporal Lobe Epilepsy and Modulation by Levetiracetam and Brivaracetam. (PubMed, Int J Mol Sci) - "These findings suggest that NECAB1 upregulation may compensate for epileptic hyperexcitability, potentially contributing to circuit remodeling via thalamocortical regulation and interneuron diversity. Levetiracetam and brivaracetam treatments partially reduced the NECAB1 density increase in TLE, indicating a modulatory effect on NECAB1 expression."

Journal • CNS Disorders • Epilepsy

Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system. (PubMed, J Neurol) - "The potential risks associated with LEV and LTG surpass expectations, warranting further evaluation, particularly in combination therapy. In addition, ASMs with widespread signals, such as VPA, CBZ, TPM, and lacosamide, warrant heightened attention."

Adverse events • Journal • CNS Disorders • Epilepsy

Brugada Pattern Induced by Acute Hyponatremia (ATS 2025) - "Continuous video electroencephalogram revealed epileptiform activity which required titration on a midazolam drip, sedation with fentanyl, and intubation. His condition eventually improved, and his seizures were controlled on brivaracetam and topiramate. Lacosamide was weaned off due to its effect on sodium channels...In the current case, many first line anti-epileptic drugs, anti-arrhythmic drugs, and sedatives such as carbamazepine, amiodarone, beta-blockers, calcium channel blockers, lidocaine, and propofol were contraindicated as they could precipitate a fatal VA...If the patient developed sustained VA, the only treatment would have been synchronized cardioversion or defibrillation. Lastly, this case demonstrates the relevance of SCN5A genetic testing for patients with both seizure disorder and Brugada Pattern, as SCN5A mutation rarely leads to both conditions."

Anesthesia • Cardiomyopathy • Cardiovascular • CNS Disorders • Epilepsy • Fibrosis • Genetic Disorders • Heart Failure • Hepatology • Immunology

Not Everything Is Behavioral: A Case Report and Systematic Review of Treatments for Severe Apneic Spells in ASD (APA 2025) - "The literature review presented here resulted in prescribing topiramate and brivaracetam. Literature search resulted in 55 publications with 9 (5 case reports, 4 reviews; total n = 36) eligible for inclusion. Treatments identified included acetazolamide, topiramate, carbamazepine, and sarizotan. Topiramate and acetazolamide were most commonly successful."

Case report • Clinical • Review • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Movement Disorders • Psychiatry

Cenobamate in Real-Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study. (PubMed, Brain Behav) - "In this large cohort of 262 PWE, CNB proved very efficient with a high retention rate over one year. Co-medication with perampanel or GABA receptor modulators was linked to seizure-freedom. The overall positive impression of CNB is further supported."

Adverse events • Journal • Retrospective data • CNS Disorders • Epilepsy

Seizure-type-specific treatment responses in Lennox-Gastaut Syndrome: A comprehensive review of pharmacological, neuromodulatory, dietary, and surgical therapies. (PubMed, Epilepsy Behav) - "Generalized tonic-clonic seizures (GTCS) show favorable responses to antiseizure medications (ASMs) such as felbamate, lamotrigine, topiramate, fenfluramine, lacosamide, and perampanel. Myoclonic seizures tend to respond better to clonazepam, topiramate, zonisamide, brivaracetam, and perampanel, but may show limited responsiveness to neuromodulation and CC. Atypical absence seizures may respond to valproate, topiramate, and rufinamide, but show poor responses to brivaracetam and perampanel...This review underscores the importance of tailoring treatment to predominant seizure types and calls for more rigorous, seizure-type-specific outcome reporting in future clinical trials, along with the need for long-term studies. The findings advocate for a precision, network-based approach to treatment, where therapeutic decisions are guided by individual seizure patterns and supported by evidence-based, seizure-type-specific efficacy data."

Journal • Review • Absence Seizure Disorder • CNS Disorders • Epilepsy

Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database. (PubMed, Acta Epileptol) - "This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use."

Adverse events • Journal • CNS Disorders • Epilepsy • Mental Retardation • Psychiatry

Effectiveness and safety of single anti-seizure medication as adjunctive therapy for drug-resistant focal epilepsy based on network meta-analysis. (PubMed, Front Pharmacol) - "Compared to placebo, the following ASMs demonstrated statistically significant effectiveness in achieving a 50% response rate: brivaracetam (RR = 2.07, 95% CI: 1.53-2.81), cenobamate (RR = 2.12, 95% CI: 1.56-2.88), eslicarbazepine acetate (RR = 1.95, 95% CI: 1.41-2.70), gabapentin (RR = 2.30, 95% CI: 1.76-3.02), lacosamide (RR = 2.22, 95% CI: 1.47-3.35), lamotrigine (RR = 1.55, 95% CI: 1.00-2.40), levetiracetam (RR = 2.43, 95% CI: 1.88-3.15), oxcarbazepine (RR = 3.03, 95% CI: 2.08-4.40), perampanel (RR = 1.72, 95% CI: 1.21-2.44), pregabalin (RR = 2.06, 95% CI: 1.70-2.50), rufinamide (RR = 2.28, 95% CI: 1.20-4.31), tiagabine (RR = 4.07, 95% CI: 2.03-8.18), topiramate (RR = 3.10, 95% CI: 2.44-3.95), vigabatrin (RR = 2.34, 95% CI: 1.58-3.46), and zonisamide (RR = 2.40, 95% CI: 1.76-3.27). Additionally, comprehensive safety data for tiagabine and levetiracetam are lacking, necessitating further research. Larger studies are required to solidify these findings and better..."

Journal • Retrospective data • Review • Ataxia • CNS Disorders • Epilepsy • Fatigue • Movement Disorders • Pain

Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control. (PubMed, Glob Reg Health Technol Assess) - "Cenobamate represents a more effective and economically advantageous treatment for patients with FOS when compared to brivaracetam, lacosamide, eslicarbazepine acetate, and perampanel. Its capacity to improve seizure control and enhance the quality of life, alongside favorable economic implications, underscores its position as the preferred therapeutic option in this patient population."

HEOR • Journal • CNS Disorders • Epilepsy

What is the difference between Levetiracetam and Brivaracetam? Characteristics and Experience (JSNE 2025) - "Co-sponsored by UCB Japan Co., Ltd."

CNS Disorders • Epilepsy

Patient-Reported Outcomes in Adults on Brivaracetam: Interim Post Hoc Analysis of Real-World Data [Encore Presentation] (JSNE 2025) - No abstract available

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Retrospective data • CNS Disorders • Epilepsy

Effectiveness/Tolerability of Adjunctive Brivaracetam: Interim Post Hoc Analysis of RealWorld Data [Encore Presentation] (JSNE 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Retrospective data • CNS Disorders • Epilepsy